Table 4.
Univariate analysis of variables correlated with overall survival
| Characteristic | 3-year OS (%) | HR (95% CI) | P -value |
|---|---|---|---|
| KPS: ≤70/>70 |
0.0 (16.2) |
5.76 (3.09-10.69) |
<0.01a |
| Gender: male/female |
11.5 (28.6) |
0.92 (0.59-1.43) |
0.71 |
| Age: >50/≤50 years |
12.5 (15.6) |
1.13 (0.53-1.30) |
0.34 |
| ALT(IU/I): >40 /≤40 |
3.8 (18.6) |
2.17 (1.32-3.57) |
<0.01a |
| Hemoglobin (g/L): <120/≥120 |
9.1 (14.9) |
1.71 (0.87-3.36) |
0.11 |
| LDH (IU/I): ≥245/<245 |
9.3 (22.6) |
1.67 (1.17-2.43) |
<0.01a |
| ALP (IU/I): ≥110/<110 |
6.9 (16.1) |
1.45 (0.91-2.31) |
0.11 |
| Number of lesions: >3/≤3 |
6.0 (25.7) |
1.90 (1.19-3.03) |
0.01a |
| Size of lesions (cm): >3/≤3 |
6.3 (18.9) |
1.22 (0.76-1.94) |
0.40 |
| Extrahepatic metastases: yes/no |
2.8 (22.4) |
1.83 (1.16-2.89) |
0.01a |
| Radiotherapy of primary tumor: no/yes |
5.7 (28.1) |
2.961 (1.79-4.75) |
<0.01a |
| Cycles of chemotherapy: (1-5) vs. ≥6 |
8.6 (18.6) |
2.20 (1.38-3.52) |
0.01a |
| Response to chemotherapy: no/yes |
0.0 (19.2) |
4.03 (2.30-7.06) |
<0.01a |
| Local therapy of lesions: no/yes | 10.4 (27.8) | 1.76 (1.02-3.04) | 0.05a |
astatistically significant; HR: hazard ratio; CI: confidence interval.